Ardenaでの出来事 – 新しい能力、新しいパートナーシップ、新しい科学。Ardenaを前進させるすべてのこと。
June 3rd, 2024 Ghent, Belgium – Ardena (the “Company”) today announces the retirement of Harry Christiaens, PhD and the subsequent appointment of Jeremie Trochu as Chief Executive Officer. Jeremie is a seasoned executive in the pharmaceutical Contract Development and Manufacturing Operations (CDMO) industry. Harry will step down as CEO after 20 years of leading the […]
Oss, The Netherlands — Ardena, a leading Contract Development and Manufacturing Organization (CDMO) specializing in bringing molecules to clinic, has received Good Manufacturing Practice (GMP) approval from the Dutch Healthcare Authority for its new analytical laboratories in its expanded nanomedicines facility. The facility includes state-of-the-art GMP-compliant cleanrooms to support Ardena’s growing nanomedicines business, as well […]
Ardena, a leading Contract Development and Manufacturing Organization (CDMO) specializing in bringing molecules to clinic, has been granted a Good Manufacturing Practice (GMP) license by the Belgian Federal Agency for Medicines and Health Products (FAMHP) for its state-of-the-art aseptic fill-finish facility in Ghent, Belgium. A significant step forward in Ardena’s ability to provide full-service solutions […]
This is a joint press release of Ardena and ELDICO Scientific AG October 18th 2023 – Oss, Netherlands and Villigen, Switzerland Ardena and ELDICO Scientific are proud to announce that today they have entered into a collaboration agreement. This partnership grants Ardena effortless access to ELDICO’s cutting-edge electron diffractometer, the ELDICO ED-1. Electron diffraction is […]
We are pleased to share Race Oncology’s latest announcement highlighting the agreement with Ardena for the manufacturing of their flagship RC220 bisantrene formulation. We are thrilled to join forces with Race Oncology and contribute to their groundbreaking work in advancing cancer therapies. According to Race Oncology’s CEO and Managing Director, Damian Clarke-Bruce, “We are pleased […]
Leading contract development manufacturer of nanomedicines, Ardena, has joined forces with mRNA and LNP technology specialists RiboPro to form a new strategic commercial alliance aimed at delivering improvements to the global availability of RNA-based health treatments and address a crucial skills gap in the industry. The new alliance combines Ardena’s expertise in custom development and […]
We are pleased to announce a major achievement in the development of our new Nanomedicines facility in Oss, Netherlands. Our team celebrated a significant milestone in the construction process yesterday by marking the highest point of the building. We were delighted to share this special moment with our esteemed partners and local authorities. As we […]
Ardena and Sciex have recently collaborated on the development of a sensitive assay for the bioanalysis of glycosphingolipids in human cerebrospinal fluid. Would you like to learn more about this assay or other lipid assays or to explore the possibilities for your research program together with us, please check the technical note or visit our […]
Our customer Vicore Pharma Holding AB has recently announced the initiation of a first-in-human trial with C106, an orally available novel drug with target engagement and anti-fibrotic effects in human fibrotic lung and kidney tissue at clinically relevant concentrations. At Ardena, we sincerely congratulate Vicore’s team on this important milestone. We are proud of our […]
Ardena acquires Idifarma from Suanfarma, adding spray drying technology and high potency capabilities Ardena, a specialist pharmaceutical Contract Development and Manufacturing Organization (CDMO), announced today that it has acquired Idifarma, a leading Contract Manufacturer of niche and highly potent generic and innovative drugs. The acquisition from Suanfarma delivers expansion across Southern Europe and supports Ardena’s […]
